- Conditions
- Breast Neoplasms
- Interventions
- Cirmtuzumab + Paclitaxel
- Drug
- Lead sponsor
- Barbara Parker, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 1,131
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HR+ HER2- Breast Cancer
- Interventions
- Serabelisib, Sapanisertib, Fulvestrant
- Drug
- Lead sponsor
- Faeth Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 71
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 654 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 45 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Breast Cancer
- Interventions
- diffusion-weighted magnetic resonance imaging
- Procedure
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 4 more
- Conditions
- Breast Cancer, Chest Wall Disease
- Interventions
- Pembrolizumab, Carboplatin, Trastuzumab
- Biological · Drug
- Lead sponsor
- Laura Huppert, MD, BA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Interventions
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
- Drug
- Lead sponsor
- Carey Anders, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Breast Cancer
- Interventions
- Palbociclib 125mg
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
- Conditions
- Breast Cancer, Brain Metastases
- Interventions
- Lapatinib, Whole Brain Radiation, Herceptin
- Drug · Procedure
- Lead sponsor
- Nancy Lin, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- HER2 Positive Breast Cancer, Cardiovascular Abnormalities
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- SM-88
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Taxotere, Cytoxan, Herceptin
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 62 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- trastuzumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells, huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
- Biological
- Lead sponsor
- Minerva Biotechnologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
- Interventions
- Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 32
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
- Conditions
- HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer
- Interventions
- Part 1, Part 2, Part 3
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Chicago, Illinois
- Conditions
- Early Breast Cancer
- Interventions
- Giredestrant
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Washington D.C., District of Columbia • Sterling Heights, Michigan + 1 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Mobile, Alabama • Boston, Massachusetts • Houston, Texas
- Conditions
- HER-2 Positive Breast Cancer
- Interventions
- Everolimus, Vinorelbine, Trastuzumab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Chapel Hill, North Carolina • Charlotte, North Carolina + 1 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Durham, North Carolina